Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 1-2, 2005, Pages 76-85

  Ledingham, Janet M ^a   Laverty, Richard ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Basilar artery; Blood pressure; Enalapril; Genetically hypertensive rat; Mesenteric resistance arteries; Morphology; Simvastatin; Valsartan

Indexed keywords

2 HYDROXYETHYL METHACRYLATE; ENALAPRIL; SIMVASTATIN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY RESISTANCE; ARTICLE; BASILAR ARTERY; BLOOD PRESSURE; BODY WEIGHT; BRAIN CIRCULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; HYPERTENSION; MESENTERIC ARTERY; NONHUMAN; RAT; STEREOMETRY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BASILAR ARTERY; BLOOD PRESSURE; BODY WEIGHT; DRUG THERAPY, COMBINATION; ENALAPRIL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MESENTERIC ARTERIES; RATS; RATS, INBRED SHR; SIMVASTATIN; TETRAZOLES; VALINE; VASCULAR RESISTANCE;

EID: 14644444448     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.04162.x     Document Type: Article

References (31)

1. Crisby M, Nordin-Fredrickson G, Shah PK et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilisation. Circulation 2001; 103: 926-33.
2. Zhao XQ, Yuan C, Hatsukami TS et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI. A case-control study. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1263-9.
3. Corti R, Fuster V, Fayid ZA et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions. Circulation 2002; 106: 2884-7.
4. Endres M, Laufs U, Huang Z et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 1998; 95: 8880-5.
5. O'Driscoll G, Green D, Taylor RR. Simvastatin, a HMG-coenzyme A reductase inhibitor, improves endothelial circulation within one month. Circulation 1997; 95: 1126-31.
6. de Sotomayor MAP, Èrez-Guerrero C, Herrera MD, Marhuenda E. Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats. J. Hypertens. 1999; 17: 769-76.
7. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischaemia and stroke. Stroke 1999; 30: 1969-73.
8. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
10. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxyl-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endithelial cells. Role of geranyl-geranylation and Rho proteins. Circ. Res. 1998; 83: 638-90.
11. Corsini A, Raiteri M, Soma M, Fumagalli R, Paoletti R. Simvastatin, but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol. Res. 1991; 23: 173-80.
12. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; ii: 1057-8.
13. Vaughan CJ, Gotto Jr AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. 2000; 35: 1-10.
14. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 566-2.
15. Aikawa M, Rabkin E, Sugiyama S et al. An HMG CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing metalloproteinases, and tissue factor in vivo and in vitro. Circulation 2001; 103: 276-83.
16. Fukumoto Y, Libby P, Rabkin E et al. Statins alter smooth muscle cell accumulation and collagen content in an established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993-9.
17. Bellosta S, Bernini F, Ferri N et al. Direct vascular effects of HMG CoA reductase inhibitors. Atherosclerosis 1998; 137 (Suppl. 1): S101-9.
18. Hirschfield G. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study): A rebuttal. Thromb. Haemost. 2001; 85: 189-90.
19. Ferner KE, Muhlman MH, Baguet J-P et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J. Am. Coll. Cardiol. 2002; 39: 1020-5.
20. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997; 30: 968-74.
21. Rèrigny O, Atkinson J, Capdeville-Atkinson C, Liminana P, Chillon J-M. Effect of lovastatin on cerebral circulation in spontaneously hypertensive rats. Hypertension 2000; 35: 1105-10.
22. Faggiotto A, Paoletti R. Statins and blockers of the renin-angiotensin system. Vascular protection beyond their primary mode of action. Hypertension 1999; 34: 987-96.
23. Ledingham JM, Laverty R. Fluvastatin remodels resistance arteries in genetically hypertensive rats even in the absence of any effect on blood pressure. Clin. Exp. Pharmacol. Physiol. 2002; 29: 931-4.
24. Ledingham JM, Phelan EL, Cross MA, Laverty R. Prevention of increases in blood pressure and left ventricular mass and remodeling of resistance arteries in young New Zealand genetically hypertensive (GH) rats: The effects of chronic treatment with valsartan, enalapril and felodipine. J. Vasc. Res. 2000; 37: 134-45.
25. Ledingham JM, Laverty R. Basilar artery remodeling in the genetically hypertensive rat: Effects of NOS inhibition and treatment with valsartan and enalapril. Clin. Exp. Pharmacol. Physiol. 2000; 27: 642-6.
26. Phelan EL. The New Zealand strain of rats with genetic hypertension. N.Z. Med. J. 1968; 67: 334-44.
27. Simpson FO, Phelan EL, Ledingham JM, Millar JA. Hypertension in the genetically hypertensive strain. In: Ganten D, De Jong W (eds). Handbook of Hypertension, Vol. 16. Experimental and Genetic Models of Hypertension. Elsevier, North Holland. 1994; 228-71.
28. Abetel G, Poget PN, Bonnabry JP. Antihypertensive effect of a cholesterol-lowering agent (fluvastatin): Pilot study. Schweiz. Med. Wochenschr. 1998; 128: 272-7.
29. Horiuchi M, Cui T-X, Li Z, Li J-M, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003; 107: 106-12.
30. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-45.
31. 1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.